Free Trial
→ Elon's next millionaires start October 24? (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$0.68
+2.4%		$0.77
$0.60
▼
$2.45
$28.66M1.48282,752 shs75,663 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
▼
$2.14
$7.94M0.688.94 million shsN/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
$3.50
-4.9%		$3.94
$3.07
▼
$10.00
$27.48M1.73158,933 shs96,067 shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$1.30
-5.1%		$1.90
$0.13
▼
$1.04
$25.04M1.581.05 million shs110,445 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-5.53%-6.38%-13.88%-29.11%-48.14%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%-89.90%-89.90%-79.80%
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
-2.13%-19.30%-5.64%-3.92%-61.43%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-2.14%-9.87%-29.38%-4.20%-74.49%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$0.68
+2.4%		$0.77
$0.60
▼
$2.45
$28.66M1.48282,752 shs75,663 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
▼
$2.14
$7.94M0.688.94 million shsN/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
$3.50
-4.9%		$3.94
$3.07
▼
$10.00
$27.48M1.73158,933 shs96,067 shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$1.30
-5.1%		$1.90
$0.13
▼
$1.04
$25.04M1.581.05 million shs110,445 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-5.53%-6.38%-13.88%-29.11%-48.14%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%-89.90%-89.90%-79.80%
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
-2.13%-19.30%-5.64%-3.92%-61.43%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-2.14%-9.87%-29.38%-4.20%-74.49%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
2.33
Hold$3.50413.12% Upside
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
1.00
SellN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OBSV, MIRA, TAOX, and VIRI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/17/2026
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$3.50
8/20/2026
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/6/2026
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/A$0.25 per shareN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
$300K91.58N/AN/A$2.83 per share1.24
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$10.44M-$1.24N/AN/AN/AN/A-106.95%-104.18%12/2/2026 (Estimated)
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
-$28.74M-$3.85N/AN/AN/A-2,153.97%-128.51%-97.54%N/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%N/A

Latest OBSV, MIRA, TAOX, and VIRI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
N/A-$1.83N/A-$1.83N/A$0.09 million
8/12/2026Q2 2026
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/A-$0.03N/A-$0.03N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
N/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/A
200.08
200.08
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
N/A
19.98
19.98
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/A
7.27
7.27

Institutional Ownership

CompanyInstitutional Ownership
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
35.16%
ObsEva SA stock logo
OBSV
ObsEva
17.52%
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
10.34%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
9.05%

Insider Ownership

CompanyInsider Ownership
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
19.89%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
2.70%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
12.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
242.02 million33.66 millionNot Optionable
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
47.85 million7.28 millionN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
519.26 million16.91 millionNo Data

Recent News About These Companies

Virios Therapeutics (NASDAQ:VIRI) Stock Falls 2.1% - Here's Why
October 14 at 2:03 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31117300
Die Virios-Therapeutics-Aktie bleibt ein spekulativer Nebenwert im Biotech-Segment
September 5, 2026  |  ad-hoc-news.deA
Digital acceptance and commitment therapy for fibromyalgia – Authors' reply
June 13, 2025  |  thelancet.comT
Dogwood Therapeutics Inc (DWTX)
March 16, 2025  |  investing.comhttps://www.investing.com/equities/virios-therapeutics-llc-news/6
Dogwood prices 578,950 shares at $8.26 in registered direct offering
March 13, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dogwood-prices-578-950-shares-at-8-26-in-registered-direct-offering-1034474303
Dogwood announces conversion of existing $19.5M in debt to equity
March 12, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dogwood-announces-conversion-of-existing-19-5m-in-debt-to-equity-1034469161
DWTX Stock trading resumes
February 11, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dwtx-stock-trading-resumes-1034343398
Dogwood Therapeutics, Inc. (DWTX)
February 2, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/DWTX/news/
DWTX Stock trading halted, volatility trading pause
January 28, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dwtx-stock-trading-halted-volatility-trading-pause-1034273379
DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth
January 23, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/dwtx-stock-hits-52-week-high-at-1574-amidst-strong-yearly-growth/ar-AA1xK7SQ
Dogwood announces first patient dosed in Phase 2b trial on Halneuron
January 21, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dogwood-announces-first-patient-dosed-in-phase-2b-trial-on-halneuron-1034250966
Polluted communities hold their breath as companies struggle with California’s diesel truck ban
December 10, 2024  |  apnews.comA
Dogwood Therapeutics faces potential Nasdaq delisting
November 23, 2024  |  uk.investing.comhttps://uk.investing.com/news/sec-filings/dogwood-therapeutics-faces-potential-nasdaq-delisting-93CH-3803100
Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue
November 18, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dogwood-says-low-dose-imc-2-treatment-reduces-long-covid-fatigue-1034031983
Dogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep Disturbance
November 18, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dogwood-study-finds-imc-2-treatment-reduces-long-covid-related-fatigue-sleep-disturbance-1034030784
Inovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News Summary
November 16, 2024  |  benzinga.comhttps://www.benzinga.com/quote/INO
DWTX: Phase 2 Long COVID Results Expected Soon
November 12, 2024  |  msn.comhttps://www.msn.com/en-us/health/medical/dwtx-phase-2-long-covid-results-expected-soon/ar-AA1tTHga
Buy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst Confidence
November 10, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/buy-rating-for-dogwood-therapeutics-strategic-initiatives-and-promising-pipeline-drive-analyst-confidence-1033984881
Dogwood Therapeutics Reports Q3 2024 Financial Results
November 9, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dogwood-therapeutics-reports-q3-2024-financial-results-1033980327
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results
November 8, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dogwood-therapeutics-announces-third-quarter-2024-financial-results-1033969465

Media Sentiment Over Time

MIRA Pharmaceuticals stock logo

MIRA Pharmaceuticals NASDAQ:MIRA

$0.68 +0.02 (+2.36%)
Closing price 04:00 PM Eastern
Extended Trading
$0.68 +0.00 (+0.13%)
As of 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Synaptogenix stock logo

Synaptogenix NASDAQ:TAOX

$3.50 -0.18 (-4.89%)
Closing price 04:00 PM Eastern
Extended Trading
$3.61 +0.11 (+3.14%)
As of 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Virios Therapeutics stock logo

Virios Therapeutics NASDAQ:VIRI

$1.30 -0.07 (-5.11%)
As of 10/13/2026

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas